Original Publication Date: 24 February, 2014
Publication / Source: Biomarkers in Medicine
Authors: Zsuzsanna Mihály, A Marcell Szász & Balázs Győrffy
Breast cancer treatment emerged as the model for tailored therapy with the introduction of antihormonal modalities and the measurement of estrogen receptors as a clinically applicable biomarker . In the adjuvant setting tamoxifen treatment is administered to reduce the risk of recurrence and death in estrogen receptor (ER)-positive breast cancer . It has been confirmed by multiple clinical trials that ER-negative tumors almost entirely fail to respond to antihormonal agents [3,4].